Viewing Study NCT02269293


Ignite Creation Date: 2025-12-25 @ 1:24 AM
Ignite Modification Date: 2026-03-09 @ 7:50 AM
Study NCT ID: NCT02269293
Status: COMPLETED
Last Update Posted: 2021-04-23
First Post: 2014-10-14
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Cancer View
None Endometrial Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Selinexor (KPT-330) View
None Paclitaxel View
None 14-110 View
None Carboplatin View